ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Jumps 5.4% – Here’s Why

Posted by Brenda Bartman on Nov 12th, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) shares traded up 5.4% during trading on Tuesday. The stock traded as high as $17.72 and last traded at $17.3980. 1,701,954 shares changed hands during mid-day trading, a decline of 5% from the average daily volume of 1,799,080 shares. The stock had previously closed at $16.50.

Analysts Set New Price Targets

ACAD has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 24th. Bank of America reiterated a “buy” rating and issued a $14.50 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Royal Bank Of Canada raised their price objective on ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Canaccord Genuity Group boosted their target price on shares of ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, October 19th. Thirteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.55.

Check Out Our Latest Research Report on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Trading Up 0.5%

The firm has a market cap of $3.17 billion, a P/E ratio of 8.71 and a beta of 0.87. The company’s 50 day simple moving average is $22.18 and its 200-day simple moving average is $23.45.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 8.90%. The firm had revenue of $342.30 million during the quarter, compared to analyst estimates of $332.58 million. During the same period in the previous year, the business posted $0.42 earnings per share. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. On average, sell-side analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.76 earnings per share for the current year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 3,321 shares of the firm’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $20.88, for a total value of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares of the company’s stock, valued at approximately $1,489,203.36. This trade represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 26.20% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rice Hall James & Associates LLC purchased a new stake in ACADIA Pharmaceuticals during the second quarter valued at approximately $15,658,000. State of Wyoming bought a new position in ACADIA Pharmaceuticals in the second quarter worth approximately $1,234,000. Virtus Advisers LLC purchased a new position in shares of ACADIA Pharmaceuticals during the 2nd quarter worth $1,123,000. Bank of America Corp DE boosted its stake in shares of ACADIA Pharmaceuticals by 27.2% during the 1st quarter. Bank of America Corp DE now owns 1,553,770 shares of the biopharmaceutical company’s stock worth $34,587,000 after acquiring an additional 332,325 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of ACADIA Pharmaceuticals during the 2nd quarter worth $1,783,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

(Get Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.